Last Updated: November 16, 2026

Donidalorsen sodium - Generic Drug Details

« Back to Dashboard


What are the generic drug sources for donidalorsen sodium and what is the scope of freedom to operate?

Donidalorsen sodium is the generic ingredient in one branded drug marketed by Ionis Pharms Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for donidalorsen sodium
International Patents:316
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:donidalorsen sodium at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for donidalorsen sodium
Generic Entry Date for donidalorsen sodium*:
Constraining patent/regulatory exclusivity:
Dosage:

SOLUTION;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for donidalorsen sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ionis Pharms Inc DAWNZERA (AUTOINJECTOR) donidalorsen sodium SOLUTION;SUBCUTANEOUS 219407-001 Aug 21, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Ionis Pharms Inc DAWNZERA (AUTOINJECTOR) donidalorsen sodium SOLUTION;SUBCUTANEOUS 219407-001 Aug 21, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Ionis Pharms Inc DAWNZERA (AUTOINJECTOR) donidalorsen sodium SOLUTION;SUBCUTANEOUS 219407-001 Aug 21, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Ionis Pharms Inc DAWNZERA (AUTOINJECTOR) donidalorsen sodium SOLUTION;SUBCUTANEOUS 219407-001 Aug 21, 2025 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for donidalorsen sodium

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3137091 C20265016 Finland ⤷  Start Trial
3524680 28/2025 Austria ⤷  Start Trial PRODUCT NAME: EPLONTERSEN, OPTIONAL IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON; REGISTRATION NO/DATE: EU/1/24/1875 (MITTEILUNG) 20250307
3137091 2026C/732 Belgium ⤷  Start Trial PRODUCT NAME: DONIDALORSEN; AUTHORISATION NUMBER AND DATE: EU/1/25/2001 20260120
3524680 301341 Netherlands ⤷  Start Trial PRODUCT NAME: EPLONTERSEN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/24/1875 20250307
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.